Business Description
Fulgent Genetics Inc
NAICS : 621511
SIC : 8071
ISIN : US3596641098
Total Employee Number:
1,315Description
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 27.92 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.17 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 4.22 | |||||
Beneish M-Score | -2.64 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -19.4 | |||||
3-Year EPS without NRI Growth Rate | -58.3 | |||||
3-Year Book Growth Rate | -6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.06 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.47 | |||||
9-Day RSI | 77.87 | |||||
14-Day RSI | 73.32 | |||||
3-1 Month Momentum % | 12.77 | |||||
6-1 Month Momentum % | -28.38 | |||||
12-1 Month Momentum % | -5.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.31 | |||||
Quick Ratio | 5.18 | |||||
Cash Ratio | 3.07 | |||||
Days Inventory | 18.71 | |||||
Days Sales Outstanding | 85.2 | |||||
Days Payable | 35.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | 8.25 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 38.71 | |||||
Operating Margin % | -33.07 | |||||
Net Margin % | -23.04 | |||||
EBITDA Margin % | -18.73 | |||||
FCF Margin % | -35.28 | |||||
OCF Margin % | -28.08 | |||||
ROE % | -6.67 | |||||
ROA % | -6.16 | |||||
ROIC % | -11.19 | |||||
3-Year ROIIC % | -1172.06 | |||||
ROC (Joel Greenblatt) % | -45.45 | |||||
ROCE % | -7.51 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 8.87 | |||||
PS Ratio | 2 | |||||
PB Ratio | 0.57 | |||||
Price-to-Tangible-Book | 0.71 | |||||
EV-to-EBIT | -3.8 | |||||
EV-to-Forward-EBIT | 3.71 | |||||
EV-to-EBITDA | -5.34 | |||||
EV-to-Forward-EBITDA | 12017.69 | |||||
EV-to-Revenue | 1 | |||||
EV-to-Forward-Revenue | 0.43 | |||||
EV-to-FCF | -2.83 | |||||
Price-to-GF-Value | 0.87 | |||||
Price-to-Projected-FCF | 0.33 | |||||
Price-to-Median-PS-Value | 0.64 | |||||
| Price-to-Net-Current-Asset-Value | 1.62 | |||||
| Price-to-Net-Cash | 3.55 | |||||
Earnings Yield (Greenblatt) % | -26.32 | |||||
FCF Yield % | -19.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fulgent Genetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 275.253 | ||
| EPS (TTM) (€) | -2.058 | ||
| Beta | 1.6726 | ||
| 3-Year Sharpe Ratio | -0.48 | ||
| 3-Year Sortino Ratio | -0.68 | ||
| Volatility % | 63.56 | ||
| 14-Day RSI | 73.32 | ||
| 14-Day ATR (€) | 0.300562 | ||
| 20-Day SMA (€) | 16.445 | ||
| 12-1 Month Momentum % | -5.92 | ||
| 52-Week Range (€) | 11.8 - 26.6 | ||
| Shares Outstanding (Mil) | 28.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fulgent Genetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fulgent Genetics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 125 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 124 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 08:30 | In 27 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 26 days | ||
| General meeting for 2026 | 2026-05-15 09:00 | 13.60 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-01 08:30 | 12.60 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-01 | 12.60 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-27 08:30 | 19.70 (+0.00%) | ||
| Annual report for 2025 | 2026-02-27 | 19.70 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-27 | 19.70 (+0.00%) |
Show
Entries
Fulgent Genetics Inc Frequently Asked Questions
What is Fulgent Genetics Inc(FRA:7F0)'s stock price today?
The current price of FRA:7F0 is €18.10. The 52 week high of FRA:7F0 is €26.60 and 52 week low is €11.80.
When is next earnings date of Fulgent Genetics Inc(FRA:7F0)?
The next earnings date of Fulgent Genetics Inc(FRA:7F0) is 2026-07-31 Est..
Does Fulgent Genetics Inc(FRA:7F0) pay dividends? If so, how much?
Fulgent Genetics Inc(FRA:7F0) does not pay dividend.
Press Release
Articles on Fulgent Genetics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers